| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 |
|---|---|---|---|---|---|---|---|---|---|
Revenue: | |||||||||
Precision oncology testing | |||||||||
211,871 | 180,462 | 151,144 | 117,295 | 93,053 | 78,407 | 60,564 | 0 | 0 | 0 |
Development services | |||||||||
33,359 | 33,913 | 33,207 | 27,900 | 17,549 | 12,232 | 8,334 | 0 | 0 | 0 |
Revenues | |||||||||
245,230 | 214,375 | 184,351 | 145,195 | 110,602 | 90,639 | 68,898 | 0 | 0 | 0 |
Costs and operating expenses: | |||||||||
Cost of precision oncology testing | |||||||||
69,423 | 62,255 | 54,875 | 47,968 | 42,824 | 39,846 | 34,825 | 0 | 0 | 0 |
Cost of development services | |||||||||
8,268 | 8,465 | 7,954 | 6,398 | 4,668 | 3,364 | 3,099 | 0 | 0 | 0 |
Research and development expense | |||||||||
106,992 | 86,292 | 77,069 | 66,753 | 58,775 | 50,714 | 41,308 | 0 | 0 | 0 |
Sales and marketing expense | |||||||||
85,643 | 78,335 | 73,162 | 67,824 | 59,960 | 53,465 | 44,159 | 0 | 0 | 0 |
General and administrative expense | |||||||||
68,523 | 61,399 | 55,087 | 46,776 | 42,334 | 36,192 | 39,740 | 0 | 0 | 0 |
Total costs and operating expenses | |||||||||
338,849 | 296,746 | 268,147 | 235,719 | 208,561 | 183,581 | 163,131 | 0 | 0 | 0 |
Loss from operations | |||||||||
-93,619 | -82,371 | -83,796 | -90,524 | -97,959 | -92,942 | -94,233 | 0 | 0 | 0 |
Interest income | |||||||||
14,574 | 13,741 | 12,204 | 8,876 | 6,766 | 5,266 | 3,589 | 0 | 0 | 0 |
Interest expense | |||||||||
900 | 1,181 | 1,159 | 1,183 | 1,213 | 1,251 | 1,255 | 0 | 0 | 0 |
Gain (Loss) on Extinguishment of Debt | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Other (expense) income, net | |||||||||
-268 | 88 | 390 | 254 | 700 | 4,702 | 4,321 | 0 | 0 | 0 |
Loss before provision for income taxes | |||||||||
-80,213 | -69,723 | -72,361 | -82,577 | -91,706 | -84,225 | -87,578 | 0 | 0 | 0 |
Provision for income taxes | |||||||||
-1,884 | -1,872 | -1,348 | -1,146 | 64 | 38 | 3 | 0 | 0 | 0 |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | |||||||||
-78,329 | -67,851 | -71,013 | -81,431 | -91,770 | -84,263 | -87,581 | 0 | 0 | 0 |
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | |||||||||
-1,000 | 7,800 | 4,550 | 5,800 | 5,500 | 800 | 950 | 0 | 0 | 0 |
Net loss attributable to Guardant Health, Inc. | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Net Income (Loss) Available to Common Stockholders, Basic | |||||||||
-77,329 | -75,651 | -75,563 | -87,231 | -97,270 | -85,063 | -93,247 | 0 | 0 | 0 |
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) | |||||||||
-0.29 | -0.27 | -0.14 | -0.13 | -0.30 | 2.05 | -1.94 | -1.75 | -1.16 | -2.76 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) | |||||||||
94,382 | 94,114 | 93,303 | 89,036 | 85,935 | 84,722 | 12,582 | 12,388 | 11,920 | 12,073 |
Series A Convertible Preferred Stock | |||||||||
Deemed dividend related to repurchase of convertible preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Series D Convertible Preferred Stock | |||||||||
Deemed dividend related to repurchase of convertible preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 0 |